Samsara BioCapital, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001744967

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q4 2025 · 21 positions · Total reported value $969.26M · Top-10 concentration 91.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 37.0% · 3 new · 7 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q4 2025 13F filing, Samsara BioCapital, LLC disclosed 21 equity positions with a combined reported value of $969.26M. The filing implies a focused portfolio: its ten largest positions account for 91.6% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were SRRK ($303.84M), MLYS ($213.06M), KLRS ($109.28M). By sector, the heaviest allocations are Health Care 99.6%, Other 0.4%. Versus the prior quarter, allocation shifted toward Health Care (+1.9pp) and away from Other (-1.9pp).

Versus the prior quarter, Samsara BioCapital, LLC opened 3 new positions, trimmed 7 and fully exited 0, a turnover rate of 37.0% of positions. The portfolio's overlap with the prior quarter was 60% of names.

The largest new positions opened in Q4 2025 were IVA ($24.16M), RANI ($11.47M), XFOR ($7.84M).

Of the 8 positions fully exited versus the prior quarter, the largest were LENZ ($15.98M), AVDL ($10.31M), AURA ($3.61M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • IVA INVENTIVA SA · $24.16M
  • RANI RANI THERAPEUTICS HLDGS INC · $11.47M
  • XFOR X4 PHARMACEUTICALS INC · $7.84M

Fully Exited (vs previous quarter)

  • LENZ LENZ THERAPEUTICS INC · prev qtr: $15.98M
  • AVDL AVADEL PHARMACEUTICALS · prev qtr: $10.31M
  • AURA AURA BIOSCIENCES INC · prev qtr: $3.61M
  • ZYME ZYMEWORKS INC · prev qtr: $3.55M
  • SRZN SURROZEN INC · prev qtr: $3.11M
  • RYTM RHYTHM PHARMACEUTICALS INC · prev qtr: $3.06M
  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $1.02M
  • BOLT BOLT BIOTHERAPEUTICS INC · prev qtr: $259.78K

Insider Transactions (Form 4)

Latest Samsara BioCapital, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Samsara BioCapital, LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 27 positions worth $1.05B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • SEC registration: 801-113741 (status: Approved), registered 2018-07-27
  • Regulatory AUM (Form ADV): $2.17B as of 2026-10-28
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds

Portfolio Structure

  • 27 positions · $1.05B reported value (Q3 2026)
  • Top 10 holdings = 87.9% of reported value
  • Largest position: SRRK (SCHOLAR ROCK HLDG CORP) at 31.7%
  • Average position size: $38.95M

Sector Tilt

  • Health Care 91.8%
  • Industrials 8.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 3 new, 3 added, 7 reduced
  • 14 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 99.6%
Other 0.4%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 6.90M $303.84M 31.35%
31.35%
Add
2 5.87M $213.06M 21.98%
21.98%
Reduce
3 12.95M $109.28M 11.28%
11.28%
Add
4 3.15M $87.80M 9.06%
9.06%
Hold
5 5.76M $56.19M 5.80%
5.80%
Add
6 1.72M $35.37M 3.65%
3.65%
Hold
7 5.19M $24.16M 2.49%
2.49%
New
8 7.22M $22.39M 2.31%
2.31%
Add
9 736.05K $19.98M 2.06%
2.06%
Reduce
10 2.50M $16.15M 1.67%
1.67%
Hold
11 968.80K $14.95M 1.54%
1.54%
Add
12 298.50K $11.94M 1.23%
1.23%
Reduce
13 8.50M $11.47M 1.18%
1.18%
New
14 104.82K $10.97M 1.13%
1.13%
Reduce
15 75.44K $10.17M 1.05%
1.05%
Hold
16 1.96M $7.84M 0.81%
0.81%
New
17 3.51M $6.49M 0.67%
0.67%
Reduce
18 60.87K $3.97M 0.41%
0.41%
Reduce
19 204.50K $2.37M 0.24%
0.24%
Reduce
20 72.25K $825.76K 0.09%
0.09%
Reduce
21 124.12K $40.96K 0.00%
0.00%
Reduce

FAQ

What did Samsara BioCapital, LLC buy in 2025-Q4?

In its 2025-Q4 13F filing, Samsara BioCapital, LLC reported 21 equity positions worth $969.26M in aggregate; its largest disclosed positions were SRRK ($303.84M), MLYS ($213.06M), KLRS ($109.28M).

How large is Samsara BioCapital, LLC's portfolio?

Samsara BioCapital, LLC reported $969.26M of long equity holdings across 21 positions as of 2025-Q4. Top-10 holdings account for 91.6% of reported value.

What is Samsara BioCapital, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/samsara-biocapital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →